Jiangsu Hengrui Medicine Gets Marketing Authorization for T-cell Lymphoma Tablets

MT Newswires Live

2024/10/14

Jiangsu Hengrui Medicine (SHA:600276) secured marketing authorization from China's State Drug Administration for its SHR2554 tablets.

The proposed indication for the tablets is for relapsed or refractory peripheral T-cell lymphoma, according to an Oct. 13 filing with the Shanghai bourse.

The pharmaceutical company has invested about 150.9 million yuan for the research and development of the SHR2554 tablets.

Shares of Jiangsu Hengrui Medicine rose 2% in recent trade.

Price (RMB): Â¥51.20, Change: Â¥+1.0, Percent Change: +1.99%

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2475387124"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2475387124\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2475387124?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-10-14 14:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2475387124","market":"sg","top_or_hot":-1,"title":"Jiangsu Hengrui Medicine Gets Marketing Authorization for T-cell Lymphoma Tablets","media":"MT Newswires Live","content":"<html><body><p> Jiangsu Hengrui Medicine (SHA:600276) secured marketing authorization from China's State Drug Administration for its SHR2554 tablets.</p><p>The proposed indication for the tablets is for relapsed or refractory peripheral T-cell lymphoma, according to an Oct. 13 filing with the Shanghai bourse.</p><p>The pharmaceutical company has invested about 150.9 million yuan for the research and development of the SHR2554 tablets.</p><p>Shares of Jiangsu Hengrui Medicine rose 2% in recent trade.</p><p>Price (RMB): Â¥51.20, Change: Â¥+1.0, Percent Change: +1.99%</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Jiangsu Hengrui Medicine Gets Marketing Authorization for T-cell Lymphoma Tablets</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJiangsu Hengrui Medicine Gets Marketing Authorization for T-cell Lymphoma Tablets\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2024-10-14 14:20</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p> Jiangsu Hengrui Medicine (SHA:600276) secured marketing authorization from China's State Drug Administration for its SHR2554 tablets.</p><p>The proposed indication for the tablets is for relapsed or refractory peripheral T-cell lymphoma, according to an Oct. 13 filing with the Shanghai bourse.</p><p>The pharmaceutical company has invested about 150.9 million yuan for the research and development of the SHR2554 tablets.</p><p>Shares of Jiangsu Hengrui Medicine rose 2% in recent trade.</p><p>Price (RMB): Â¥51.20, Change: Â¥+1.0, Percent Change: +1.99%</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0405327494.USD","symbol_name":"ALLSPRING CHINA A FOCUS \"I\" (USD) ACC","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2475387124","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2475387124","pubTimestamp":1728886815,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Jiangsu Hengrui Medicine  secured marketing authorization from China's State Drug Administration for its SHR2554 tablets.The proposed indication for the tablets is for relapsed or refractory peripheral T-cell lymphoma, according to an Oct. 13 filing with the Shanghai bourse.The pharmaceutical company has invested about 150.9 million yuan for the research and development of the SHR2554 tablets.Shares of Jiangsu Hengrui Medicine rose 2% in recent trade.Price : 51.20, Change: +1.0, Percent Change: +1.99%","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"600276":"恒瑞医药","LU0405327494.USD":"ALLSPRING CHINA A FOCUS \"I\" (USD) ACC","LU1328615791.USD":"FULLERTON LUX FUNDS - ALL CHINA EQUITIES \"I\" (USD) ACC","BK0183":"MSCI概念","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","BK0239":"医药制造","BK0188":"融资融券","LU1064130708.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"I\" (USD) ACC","LU1064131003.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"A\" (USD) ACC","BK0012":"证金概念","LU2148510915.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"R\" (USD) ACC","BK0196":"行业龙头","BK0060":"抗癌","LU0405327148.USD":"ALLSPRING CHINA A FOCUS \"A\" (USD) ACC","BK0028":"国家队"},"translate_title":"江苏恒瑞医药T细胞淋巴瘤片获上市许可","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600276":0.9},"content_text":"Jiangsu Hengrui Medicine (SHA:600276) secured marketing authorization from China's State Drug Administration for its SHR2554 tablets.The proposed indication for the tablets is for relapsed or refractory peripheral T-cell lymphoma, according to an Oct. 13 filing with the Shanghai bourse.The pharmaceutical company has invested about 150.9 million yuan for the research and development of the SHR2554 tablets.Shares of Jiangsu Hengrui Medicine rose 2% in recent trade.Price (RMB): Â¥51.20, Change: Â¥+1.0, Percent Change: +1.99%","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}